Growing concerns over the diminishing effectiveness of antifungal medications are prompting new scrutiny of agricultural practices, as a newly released report suggests a link between fungicide use in farming and the rise of treatment-resistant fungal infections in humans.The report, from researchers at the netherlands’ National Institute for Public Health and the Surroundings, highlights the potential for “cross-resistance” – where fungal resistance developed in crops transfers to human pathogens-and calls for a reevaluation of regulatory approval processes for these compounds. This issue impacts a range of patients,from those with compromised immune systems to individuals with common fungal illnesses,and could signal a critical turning point in the fight against increasingly resilient fungal diseases.
Antifungal medications are becoming less effective against common fungal infections like Aspergillus fumigatus and Candida, raising concerns about treatment options for patients. A new report suggests a link between the use of these same antifungal agents in agriculture and the development of resistance in human-affecting fungi.
The growing resistance stems from the widespread use of azole antifungal drugs, which are also frequently applied in agricultural settings. Fungi exposed to these chemicals in crops can develop resistance, and that resistance can then transfer to similar medications used to treat human infections. This poses a significant public health challenge, as fungal infections can range from mild to life-threatening, particularly for individuals with compromised immune systems.
Researchers at the Netherlands’ National Institute for Public Health and the Environment (RIVM) are recommending that regulators consider this “cross-resistance” when approving new antifungal substances for agricultural use. Currently, cross-resistance is not a standard factor in the approval process. The report, titled Resistente schimmelinfecties door het gebruik van dezelfde antischimmelstoffen bij mensen en landbouwgewassen, highlights the potential for resistance to spread.
The RIVM also advises limiting the use of antifungals in agriculture whenever possible and reserving certain compounds specifically for human medical applications. Further research is needed to understand how resistant fungi spread from the environment to infect patients in healthcare settings, according to the report.
While many fungal infections are relatively harmless, they can become serious, even fatal, for vulnerable populations such as cancer patients, individuals with HIV/AIDS, and those who have received organ transplants. Cross-resistance to azoles has already been demonstrated in Aspergillus fumigatus, making infections with this fungus more difficult to treat. The findings suggest this issue may extend to other fungal species as well.
Evidence indicates that cross-resistance may also be emerging in various Candida species, with resistant strains already identified in environmental samples. Additionally, the RIVM warns that newly developed antifungal agents could face the same resistance issues if they are used in both agriculture and human medicine. This underscores the need for careful consideration of drug usage across different sectors.
The RIVM conducted this research at the request of the Dutch Ministry of Agriculture, Fisheries, Food Safety and Nature. The report’s conclusions could influence future policies regarding antifungal use and help to protect the effectiveness of these vital medications.
Copyright ©2025 AgriHolland B.V.
